KR20160026452A - Compositions for improving skin wrinkle or enhancing skin elasticity comprising breviscapine - Google Patents
Compositions for improving skin wrinkle or enhancing skin elasticity comprising breviscapine Download PDFInfo
- Publication number
- KR20160026452A KR20160026452A KR1020140115382A KR20140115382A KR20160026452A KR 20160026452 A KR20160026452 A KR 20160026452A KR 1020140115382 A KR1020140115382 A KR 1020140115382A KR 20140115382 A KR20140115382 A KR 20140115382A KR 20160026452 A KR20160026452 A KR 20160026452A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- collagen
- breviscapine
- present
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 62
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 title claims abstract description 53
- DJSISFGPUUYILV-UHFFFAOYSA-N UNPD161792 Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-UHFFFAOYSA-N 0.000 title claims abstract description 52
- 230000037303 wrinkles Effects 0.000 title claims abstract description 44
- 230000037394 skin elasticity Effects 0.000 title claims abstract description 28
- 230000002708 enhancing effect Effects 0.000 title 1
- 102000008186 Collagen Human genes 0.000 claims abstract description 40
- 108010035532 Collagen Proteins 0.000 claims abstract description 40
- 229920001436 collagen Polymers 0.000 claims abstract description 39
- 239000002537 cosmetic Substances 0.000 claims abstract description 35
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 27
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 27
- 239000004480 active ingredient Substances 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 3
- 230000006872 improvement Effects 0.000 abstract description 27
- 230000000694 effects Effects 0.000 abstract description 26
- 235000013305 food Nutrition 0.000 abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 14
- 238000009472 formulation Methods 0.000 abstract description 12
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 210000003491 skin Anatomy 0.000 description 67
- 150000003839 salts Chemical class 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 18
- 239000000686 essence Substances 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 210000002950 fibroblast Anatomy 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- -1 alkaline earth metal salt Chemical class 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 102000012422 Collagen Type I Human genes 0.000 description 10
- 108010022452 Collagen Type I Proteins 0.000 description 10
- 239000006071 cream Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 102000001187 Collagen Type III Human genes 0.000 description 7
- 108010069502 Collagen Type III Proteins 0.000 description 7
- 108010014258 Elastin Proteins 0.000 description 7
- 102000016942 Elastin Human genes 0.000 description 7
- 229920002549 elastin Polymers 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000037319 collagen production Effects 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 5
- 229930003268 Vitamin C Natural products 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- 238000011891 EIA kit Methods 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 210000004177 elastic tissue Anatomy 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000010191 image analysis Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 239000008278 cosmetic cream Substances 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 108090000672 Annexin A5 Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 230000004215 skin function Effects 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- VEVRNHHLCPGNDU-MUGJNUQGSA-N (2s)-2-amino-5-[1-[(5s)-5-amino-5-carboxypentyl]-3,5-bis[(3s)-3-amino-3-carboxypropyl]pyridin-1-ium-4-yl]pentanoate Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- BNNMDMGPZUOOOE-UHFFFAOYSA-N 4-methylbenzenesulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1 BNNMDMGPZUOOOE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229930193712 breviscapin Natural products 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000008234 soft water Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 피부 주름 개선 또는 피부 탄력 증진과 관련된 조성물, 특히 화장료, 식품, 또는 약학 조성물에 관한 것으로, 적은 양으로도 피부 주름 개선 및 피부 탄력 증진 효과가 우수한 화장료, 식품, 또는 약학 조성물에 관한 것이다. 본 발명의 화장료, 식품, 또는 약학적 조성물은 콜라겐, 특히 제1형 및 제3형 콜라겐의 강력한 합성 촉진 활성을 갖는 브레비스카핀(breviscapine)을 포함하여 피부 주름 개선 및 피부 탄력 증진 효과가 우수하다. 또한, 브레비스카핀은 안정성이 우수하여 인체에 무해하고, 이를 포함하는 화장료, 식품, 또는 약학적 조성물은 제형 제작이 용이하며, 제형 안정성 또한 우수하다.The present invention relates to a composition, particularly a cosmetic composition, a food or a pharmaceutical composition, which relates to the improvement of skin wrinkles or skin elasticity, and relates to a cosmetic composition, a food or a pharmaceutical composition excellent in skin wrinkle and skin elasticity . The cosmetic, food or pharmaceutical composition of the present invention includes brevis capine having a strong synthesis promoting activity of collagen, especially collagen of type 1 and type 3, and is excellent in skin wrinkle improvement and skin elasticity enhancement effect. In addition, Breviscaffin is excellent in stability and is harmless to the human body, and a cosmetic, food, or pharmaceutical composition containing the same is easy to formulate and has excellent formulation stability.
Description
본 발명은 피부 주름 개선 또는 피부 탄력 증진과 관련된 조성물, 특히 화장료, 식품, 또는 약학 조성물에 관한 것으로, 적은 양으로도 피부 주름 개선 및 피부 탄력 증진 효과가 우수한 화장료, 식품, 또는 약학 조성물에 관한 것이다.The present invention relates to a composition, particularly a cosmetic composition, a food or a pharmaceutical composition, which relates to the improvement of skin wrinkles or skin elasticity, and relates to a cosmetic composition, a food or a pharmaceutical composition excellent in skin wrinkle and skin elasticity .
피부는 외부 환경으로부터 인체를 보호하고, 내부의 수분 및 유용 성분이 밖으로 유출되는 것을 막아주는 장벽기능, 체온조절, 또는 배설 등 다양한 생리적 기능을 담당하고 있는 중요한 기관이다. 일반적으로 피부는 다양한 외부자극과 접하는 기회가 많기 때문에 다른 기관들에 비해 주름이 발생하기 쉽다. 그 중에서도 얼굴 피부는 태양광선, 건조한 환경, 또는 공해 물질 등에 직접적으로 노출되어 있어 외부에 노출되지 않은 피부보다 주름 등의 노화현상이 조기에 발생한다.Skin is an important organ that is responsible for various physiological functions such as barrier function, body temperature control, or excretion, which protects the human body from the external environment and prevents the internal moisture and useful components from flowing out. Generally, the skin is more prone to wrinkles than other organs because it has many opportunities to interact with various external stimuli. Among them, facial skin is exposed directly to sunlight, dry environment, pollutants, etc., so that aging phenomenon such as wrinkles occurs earlier than skin not exposed to the outside.
피부 조직의 노화에 따른 가장 특징적인 변화는 피부 기질(matrix)의 변화로서, 진피층에 있는 섬유아세포(human skin fibroblast)가 노화되어 섬유질과 기질의 생성능력이 줄어들게 된다. 기질의 양이 전반적으로 감소하여 피부의 두께가 얇아지고 피부의 탄력이 저하되면서 주름이 형성되게 된다. 즉, 노화가 진행됨에 따라 피부는 탄력성의 저하, 혈액순환의 장애, 또는 피부 장벽의 약화 등이 더욱 심해지게 된다.The most characteristic change due to aging of the skin tissue is a change in the skin matrix, which causes aging of the human skin fibroblast in the dermis, resulting in a decrease in the ability to produce fibrous and matrix. The amount of the substrate is generally decreased, and the thickness of the skin is thinned, and the elasticity of the skin is lowered and wrinkles are formed. That is, as the skin ages, the skin becomes less elastic, the blood circulation becomes disordered, or the skin barrier becomes weaker.
콜라겐은 피부의 섬유아세포에서 생성되는 주요 기질 단백질로써 세포 외 간질에 존재하고, 중요한 기능으로는 피부의 기계적 견고성, 결합조직의 저항력과 조직의 결합력, 및 세포사이의 부착을 통한 지탱력 등을 제공하는 것으로 알려져 있다. 콜라겐은 생체 단백질 총 중량의 약 30%를 차지하는 주요 단백질로서 견고한 3중 나선 구조를 가지고 있다. 콜라겐은 피부, 건(tendon), 뼈 및 치아의 유기 물질 대부분을 형성하는데, 특히 뼈와 피부(진피)에 그 함량이 높다. 피부에는 제1형 콜라겐(type I collagen) 및 제3형 콜라겐(type III collagen)이 존재하고 있다. 그 중에서 제1형 콜라겐이 많은 부분을 차지하고 제3형 콜라겐은 적게 존재하고 있지만 이 두 종류의 콜라겐 모두 연령 및 자외선과 같은 외부 자극에 의해 감소하며, 이는 피부의 주름 형성과 밀접한 연관이 있음이 잘 알려져 있다. Collagen is a major substrate protein produced in the fibroblasts of the skin and exists in extracellular epilepsy. Its important functions are mechanical rigidity of the skin, resistance of connective tissues and binding force of tissues, and support through adhesion between cells. . Collagen is a major protein that accounts for about 30% of the total biomass protein weight and has a solid triple helix structure. Collagen forms most of the organic matter in the skin, tendons, bones and teeth, especially in the bones and skin (dermis). Type I collagen (type I collagen) and type III collagen (type III collagen) are present in the skin. Among them, type 1 collagen accounts for a large portion and type 3 collagen is small, but both types of collagen are reduced by external stimuli such as age and ultraviolet rays, and this is closely related to the formation of wrinkles of the skin It is known.
종래에는 콜라겐의 피부 보습효과를 이용하여 화장품에 콜라겐을 배합하는 제품들이 출시되어 있으나, 이들 화장품은 콜라겐을 피부 표면에 도포하는 것으로, 고분자인 콜라겐의 경피 흡수는 매우 어려우므로 콜라겐의 피부 흡수에 의한 작용을 기대하기 어려워 본질적인 피부 기능 개선이라고 말할 수 없다.In the prior art, there have been products in which collagen is formulated into cosmetics using the skin moisturizing effect of collagen. However, since these cosmetics are coated with collagen on the skin surface, transdermal absorption of collagen as a polymer is very difficult, It is difficult to expect the action, so it can not be said that improvement of essential skin function.
종래에 알려진 콜라겐 합성 촉진 물질로는 레티노익산(retinoic acid), 형질전환성장인자(TGF: transforming growth factor)(Cardinale G. et al, Adv. Enzymol., 41, p. 425, 1974), 동물 태반 유래 단백질(일본특개평 8-231370), 베툴린산(betulinic acid)(일본특개평 8-208424), 클로렐라 추출물(일본특개평 9-40523, 일본특개평 10-36283, 섬유아세포 증식 촉진작용) 등 많은 물질들이 알려져 있다. 그러나, 이들 물질을 피부에 적용 시 자극, 발적 등 안전성의 문제로 사용에 제한이 있거나 실제적 효과가 미미하여 피부 기능 개선 효과를 기대할 수 없다. 따라서, 기존의 피부 주름 개선 화장료 조성물보다 생체에 안전하고 효과가 높은 새로운 피부 주름 개선용 화장료 조성물의 개발이 절실히 요구되고 있다.Conventional collagen synthesis promoting substances include retinoic acid, transforming growth factor (TGF) (Cardinale G. et al, Adv. Enzymol., 41, p. 425, 1974), animal placenta (Japanese Patent Application Laid-Open No. 8-231370), betulinic acid (Japanese Patent Application Laid-Open No. 8-208424), chlorella extract (Japanese Patent Application Laid-Open No. 9-40523, Japanese Laid-Open Patent Application No. 10-36283, Many materials are known. However, when these substances are applied to the skin, there is a limitation in use due to safety issues such as irritation and redness, or the effect of improving the skin function can not be expected because the effect is insignificant. Therefore, it is urgently required to develop a cosmetic composition for improving skin wrinkles, which is safer and more effective for a living body than a conventional skin wrinkle improving cosmetic composition.
따라서 본 발명이 해결하고자 하는 과제는 위와 같은 문제점을 해결하고, 부작용이 적고 인체에 안전하면서도 피부 개선, 특히 피부 주름 개선 또는 피부 탄력 증진 효과가 우수한 새로운 활성 성분, 즉, 활성 성분의 이러한 유용한 용도를 제공하는 것이다.Therefore, a problem to be solved by the present invention is to solve the above-mentioned problems, and to provide a new active ingredient which is low in side effects and safe for human body, and which is excellent in skin improvement, particularly skin wrinkle improvement or skin elasticity improvement effect, .
다시 말해, 본 발명이 해결하고자 하는 과제는 상기 효능이 우수한 활성 성분을 유효성분으로 포함하는 조성물을 제공하는 것이다.In other words, a problem to be solved by the present invention is to provide a composition comprising an active ingredient having excellent efficacy as an active ingredient.
상기 과제를 해결하기 위하여, 본 발명은 브레비스카핀(breviscapine) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 조성물을 제공한다. In order to solve the above problems, the present invention provides a composition comprising breviscapine or a pharmaceutically acceptable salt thereof as an active ingredient.
보다 구체적으로, 본 발명은 브레비스카핀(breviscapine) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 외용제를 제공한다. More specifically, the present invention provides an external preparation for skin comprising breviscapine or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명은 브레비스카핀(breviscapine) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 화장료 조성물을 제공한다. The present invention provides a cosmetic composition comprising breviscapine or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명은 브레비스카핀(breviscapine) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 주름 개선 또는 피부 탄력 증진용 조성물, 바람직하게는 화장료, 식품, 또는 약학 조성물을 제공한다.The present invention provides a composition for improving skin wrinkles or skin elasticity, preferably a cosmetic, a food or a pharmaceutical composition comprising breviscapine or a pharmaceutically acceptable salt thereof as an active ingredient.
바람직하게, 본 발명은 브레비스카핀(breviscapine) 또는 이의 약학적으로 허용 가능한 염의 피부 주름 개선 또는 피부 탄력 증진용이라는 새로운 용도를 제공한다.Preferably, the present invention provides a new use for improving skin wrinkles or improving skin elasticity of breviscapine or a pharmaceutically acceptable salt thereof.
본 발명의 발명자들은 소량으로 인체에 안전하게 콜라겐 합성을 촉진하는 효과를 갖는 물질을 개발하기 위해 예의 노력한 결과, 브레비스카핀(breviscapine)이 제1형과 제3형 콜라겐 모두에 매우 효과적으로 합성 촉진 효과가 있음을 밝혀내고, 이를 피부 개선, 특히 주름 개선 또는 피부 탄력 증진을 위해 사용할 수 있음을 확인함으로써, 본 발명을 완성하게 되었다. As a result of intensive efforts to develop a substance having an effect of promoting collagen synthesis safely in the human body in a small amount, the inventors of the present invention have found that Breviscapine is highly effective in promoting synthesis of both type 1 and type 3 collagen And confirmed that it can be used for skin improvement, particularly wrinkle improvement or skin elasticity enhancement, thereby completing the present invention.
본 발명에 있어서 '피부 개선'는 브레비스카핀이 피부에 흡수되어 나타내는 유리한 효과를 통칭하며, 피부에의 유리한 효과는 피부 상태 및/또는 기능이 유지, 호전되는 것을 의미하고, 예컨대, 브레비스카핀의 콜라겐 합성 촉진 효과 및 이에 의한 피부 주름 개선 또는 피부 탄력 증진이 포함된다. In the present invention, 'skin improvement' refers to favorable effects of Breviscaffin absorbed by the skin. The beneficial effect on the skin means that the skin condition and / or function is maintained and improved. For example, Breviscapin collagen Promoting synergy and thereby improving skin wrinkles or skin elasticity.
본 발명에 있어서 '피부 주름'는 피부가 노화하여 생긴 작은 줄을 의미하는데 유전자에 의한 원인, 피부 진피에 존재하는 콜라겐과 엘라스틴의 감소, 또는 외부환경 등에 의해 유발될 수 있다.In the present invention, 'skin wrinkles' refers to small lines formed by aging of skin, which may be caused by genes, by reduction of collagen and elastin present in skin dermis, or by external environment.
본 발명에 있어서 '피부 주름 개선'는 피부에 주름이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 주름을 완화시키는 것을 의미한다.In the present invention, " improvement of skin wrinkles " means suppressing or inhibiting the generation of wrinkles on the skin, or alleviating already formed wrinkles.
본 발명에 있어서 '피부 탄력'는 진피층에 존재하는 엘라스틴(elastin)으로 구성된 탄력섬유에 의해 나타나는데, 이러한 탄력섬유는 고무와 같이 매우 낮은 탄성계수를 가지고 있어서 작은 힘에 의해서도 쉽게 변형되고, 또 그 힘이 제거되었을 때는 쉽게 원형으로 되돌아온다. 또한, 탄력섬유는 엘라스틴이라는 무정형의 기질에 미원섬유(microfibirls)들이 박혀 있는 구조를 띠고 있으며, 엘라스틴은 라이신에서 유래한 데스모신(desmosine)과 이소데스코신(isodesmosine) 이라는 탄력섬유에서만 발견되는 아주 독특한 아미노산으로 구성된 단백질이다. 이러한 데스모신과 아이소데스모신 등은 긴 펩타이드 사슬안에서 가교(cross-links)를 형성하고 있는데, 이러한 구조가 엘라스틴으로 하여금 고무와 같은 성질을 갖게 한다.In the present invention, "skin elasticity" is represented by elastic fibers composed of elastin existing in the dermal layer. Such elastic fibers have a very low elastic modulus such as rubber and are easily deformed by a small force, When removed, it easily returns to the original shape. Elastic fibers have a structure in which microfibirls are embedded in an amorphous substrate called elastin. Elastin is a very unique substance found only in the elastic fibers of lysine-derived desmosine and isodesmosine It is a protein composed of amino acids. These desmosins and isodesmesynes form cross-links in long peptide chains, which makes elastin behave like a rubber.
본 발명에 있어서 '피부 탄력 증진'란, 엘라스틴(elastin)으로 구성된 탄력섬유가 콜라겐(collagen)이라고 하는 교원섬유와 함께 존재하는데, 엘라스틴과 콜라겐이 충분히 존재하는 상태에서 피부의 탄력성이 향상되는 것을 말한다.
In the present invention, 'skin elasticity enhancement' refers to elasticity fibers composed of elastin together with collagen fibers, which improve skin elasticity in a state where elastin and collagen are present sufficiently .
보다 구체적으로, 본 발명은 하기 화학식 1로 대표되는 화합물 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 조성물을 제공한다.More specifically, the present invention provides a composition comprising a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient.
[화학식 1][Chemical Formula 1]
상기 화학식 1로 대표되는 화합물은 브레비스카핀(breviscapine)이며, 가능한 모든 이성질체를 포함할 수 있다.The compound represented by the general formula (1) is breviscapine and may include all possible isomers.
본 발명은 상기 브레비스카핀의 획득 방법에 특별히 한정되지 않으며, 일반적인 화학합성으로 수득되거나, 천연물로부터 분리되거나, 또는 판매되는 것을 구입하여 사용할 수 있다.The present invention is not particularly limited to the method for obtaining Breviscaffin, and can be obtained by general chemical synthesis, separated from natural products, or sold.
본 발명의 조성물의 유효성분으로서 상기 브레비스카핀(breviscapine)은 이의 약학적으로 허용 가능한 염의 형태로 사용될 수 있는데, 염기를 사용하여 약제학적으로 허용 가능한 금속염으로 만들어 사용할 수 있다. 알칼리 금속 또는 알칼리 토금속 염의 경우, 화합물을 과량의 알칼리 금속 수산화물 또는 알칼리 토금속 수산화물 용액 중에 용해시키고, 비용해 화합물 염을 여과한 후 여액을 증발, 건조시켜 얻을 수 있다. 이때, 금속염으로는 특히 나트륨, 칼륨, 또는 칼슘염 등을 제조하는 것이 제약상 적합하나, 이들에 제한되는 것은 아니다. 또한, 이에 대응하는 은염은 알칼리 금속 또는 알칼리 토금속 염을 적당한 은염(예, 질산은)과 반응시켜 얻을 수 있다.Breviscapine as an active ingredient of the composition of the present invention can be used in the form of a pharmaceutically acceptable salt thereof, and can be used as a pharmaceutically acceptable metal salt using a base. In the case of an alkali metal or an alkaline earth metal salt, the compound can be obtained by dissolving the compound in an excess amount of an alkali metal hydroxide or an alkaline earth metal hydroxide solution, filtering the insoluble compound salt, and evaporating and drying the filtrate. At this time, as the metal salt, sodium, potassium, calcium salt and the like are preferably formulated for pharmaceuticals, but the present invention is not limited thereto. The corresponding silver salt can also be obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (e.g., silver nitrate).
상기 브레비스카핀(breviscapine)의 약제학적으로 허용 가능한 염은, 달리 지시되지 않는 한, 브레비스카핀(breviscapine)의 화합물에 존재할 수 있는 산성 또는 염기성 기의 염을 포함할 수 있다. 약학적으로 허용 가능한 염으로는 예를 들어, 히드록시기의 나트륨, 칼슘, 또는 칼륨 염 등이 포함될 수 있고, 아미노기의 기타 약학적으로 허용 가능한 염으로는 히드로브로마이드, 황산염, 수소 황산염, 인산염, 수소 인산염, 이수소 인산염, 아세테이트, 숙시네이트, 시트레이트, 타르트레이트, 락테이트, 만델레이트, 메탄술포네이트(메실레이트), 또는 p-톨루엔술포네이트(토실레이트) 염 등이 있으며, 당업계에서 통상적으로 사용되는 염의 제조방법을 통하여 제조될 수 있다.The pharmaceutically acceptable salts of breviscapine may, unless otherwise indicated, include salts of acidic or basic groups that may be present in compounds of breviscapine. Pharmaceutically acceptable salts may include, for example, the sodium, calcium, or potassium salts of the hydroxy group, and the other pharmaceutically acceptable salts of the amino group include hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate (Hydrogen phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulfonate (mesylate), or p-toluenesulfonate (tosylate) salts, Can be prepared through a method for producing a salt to be used.
본 발명에서 상기 브레비스카핀(breviscapine)은 이와 동일한 효능을 갖는 범위 내에서, 이의 유도체(derivatives)를 포함할 수 있다. 또한 상기 브레비스카핀(breviscapine)은 이로부터 제조될 수 있는 동일한 효능을 나타내는 용매 화합물, 또는 수화물 등을 포함할 수 있다.
In the present invention, breviscapine may include derivatives thereof within the range of the same efficacy. The breviscapine may also contain a solvent, hydrate, or the like that exhibits the same potency as can be prepared therefrom.
본 발명의 브레비스카핀(breviscapine)은 콜라겐 합성 촉진제로서 사용될 수 있다.Breviscapine of the present invention can be used as collagen synthesis promoter.
본 발명의 브레비스카핀(breviscapine)을 포함하는 조성물은 콜라겐, 보다 구체적으로 제1형 콜라겐(type I collagen) 및 제3형 콜라겐(type III collagen)의 합성을 촉진함으로써 피부 주름 개선 또는 피부 탄력 증진 효과를 나타낸다. 본 발명의 실시예에서는 인간 유래의 섬유아세포의 배양액에 본 발명의 조성물을 투여한 후, 생합성 된 2가지 종류의 콜라겐의 양을 측정한 결과, 상기 브레비스카핀(breviscapine)이 농도의존적으로 두 종류의 콜라겐 합성을 증가시켜 인간 유래 섬유아세포에 대하여 우수한 제1형 콜라겐 및 제3형 콜라겐 합성능이 있음을 확인하였다(실시예 1, 실시예 2, 표2, 표3). 또한 본 별명의 실시예에서는 눈 밑 주름에 대한 영상분석을 통해 피부 주름 개선 효과를 측정한 결과, 상기 브레비스카핀(breviscapine)을 처리한 부위가 대조군(무처리)에 비해 우수한 주름 개선 효과를 가짐을 확인하였다(실시예 4, 표8).
The composition comprising Breviscapine of the present invention promotes the synthesis of collagen, more specifically type 1 collagen (type I collagen) and type 3 collagen (type III collagen), thereby improving skin wrinkles or improving skin elasticity . In the examples of the present invention, after the composition of the present invention was administered to a culture medium of human-derived fibroblasts, the amounts of two types of collagen biosynthesized were measured. As a result, it was found that the breviscapine contained two types of collagen Collagen synthesis was increased, and it was confirmed that excellent collagen type 1 and type 3 collagen synthesis ability was obtained for human-derived fibroblasts (Example 1, Example 2, Table 2, Table 3). Also, in the embodiment of this alias, the wrinkle improvement effect was evaluated by image analysis of under-wrinkles, and as a result, the area treated with brevis capine had a wrinkle-reducing effect superior to that of the control group (untreated) (Example 4, Table 8).
본 발명은 상기 브레비스카핀(breviscapine) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 주름 개선 또는 피부 탄력 증진용 화장료 조성물을 제공한다.The present invention provides a cosmetic composition for improving skin wrinkles or skin elasticity comprising the above-mentioned breviscapine or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명의 화장료 조성물은 브레비스카핀(breviscapine)을 조성물 총 중량에 대하여 1x10-6 내지 10 중량%로 포함할 수 있으며, 보다 바람직하게는 0.001 내지 10 중량%, 가장 바람직하게는 0.1 중량% 내지 10 중량%로 포함할 수 있다. 상기 함량이 1x10-6 중량% 미만인 경우에는 뚜렷한 효과를 기대할 수 없고, 10 중량%를 초과하는 경우에는 함량 증가에 비해 효과의 증가가 미치지 못한다.The cosmetic composition of the present invention may comprise 1 × 10 -6 to 10% by weight, more preferably 0.001 to 10% by weight, and most preferably 0.1 to 10% by weight of brevis capine, %. When the content is less than 1 x 10-6 wt%, no significant effect can be expected. When the content is more than 10 wt%, the effect is not increased more than the content increase.
본 발명에 따른 피부 주름 개선 또는 피부 탄력 증진용 화장료 조성물은 용액, 외용 연고, 크림, 폼, 영양화장수, 유연화장수, 팩, 유연수, 유액, 메이크업베이스, 에센스, 비누, 액체 세정료, 입욕제, 선 스크린크림, 선오일, 현탁액, 유탁액, 페이스트, 겔, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 패취, 및 스프레이 등으로 이루어진 군에서 선택되는 제형으로 제조할 수 있으나, 이에 제한되는 것은 아니다.The cosmetic composition for improving skin wrinkles or improving skin elasticity according to the present invention can be used as a solution, an external ointment, a cream, a foam, a nutritional lotion, a softening water, a pack, a soft water, a milky lotion, a makeup base, an essence, a soap, But are not limited to, those selected from the group consisting of screen cream, sun oil, suspension, emulsion, paste, gel, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, patch, But are not limited thereto.
또한, 본 발명의 화장료 조성물은 일반 피부 화장료에 배합되는 화장품학적으로 허용 가능한 담체를 1종 이상 추가로 포함할 수 있으며, 통상의 성분으로 예를 들면 유분, 물, 계면활성제, 보습제, 저급 알코올, 증점제, 킬레이트제, 색소, 방부제, 및 향료 등으로 이루어진 군에서 선택된 하나 이상을 적절히 배합할 수 있으나, 이에 제한되는 것은 아니다.In addition, the cosmetic composition of the present invention may further comprise at least one cosmetically acceptable carrier incorporated in a cosmetic composition for general skin, and examples thereof include oil, water, a surfactant, a moisturizer, a lower alcohol, A thickener, a chelating agent, a coloring matter, a preservative, and a perfume, but the present invention is not limited thereto.
본 발명의 화장료 조성물에 포함되는 화장품학적으로 허용 가능한 담체는 제형에 따라 다양하다. 본 발명의 화장료의 제형이 외용 연고, 페이스트, 크림, 또는 젤인 경우에는, 담체성분으로 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화아연, 또는 이들의 혼합물 등이 이용될 수 있다.The cosmetically acceptable carrier to be contained in the cosmetic composition of the present invention varies depending on the formulations. When the formulation of the cosmetic composition of the present invention is an external ointment, paste, cream, or gel, it is preferable to use an animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, , Zinc oxide, or a mixture thereof, and the like can be used.
본 발명의 화장료의 제형이 파우더 또는 스프레이인 경우에는, 담체 성분으로 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더, 또는 이들의 혼합물 등이 포함될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄, 또는 디메틸 에테르 등과 같은 추진제가 포함될 수 있다.When the formulation of the cosmetic of the present invention is a powder or a spray, the carrier component may include lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or a mixture thereof, Propellants such as chlorofluorohydrocarbons, propane / butane, dimethyl ether, and the like may additionally be included.
본 발명의 화장료의 제형이 용액 또는 유탁액인 경우에는, 담체 성분으로서 용매, 용해화제, 또는 유탁화제가 이용될 수 있다. 보다 구체적으로, 화장료 제형이 용액 또는 유탁액인 경우에는 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 목화씨 오일, 땅콩 오일, 옥수수 배종 오일, 올리브 오일, 피마자 오일, 참깨 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜, 및 소르비탄 지방산 에스테르 등으로 이루어진 군에서 선택된 하나 이상이 포함될 수 있다.When the formulation of the cosmetic of the present invention is a solution or an emulsion, a solvent, a dissolving agent or an emulsifying agent may be used as a carrier component. More specifically, when the cosmetic formulation is a solution or an emulsion, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, cotton seed oil, peanut oil, corn oil , Olive oil, castor oil, sesame oil, glycerol aliphatic ester, polyethylene glycol, sorbitan fatty acid ester, and the like.
본 발명의 화장료의 제형이 현탁액인 경우에는, 담체 성분으로서 물, 에탄올, 및 프로필렌 글리콜 등과 같은 액상의 희석제; 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르, 및 폴리 옥시에틸렌 소르비탄 에스테르 등과 같은 현탁제; 및 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가, 및 트라칸트 등으로 이루어진 군에서 선택된 하나 이상이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a suspension, a liquid diluent such as water, ethanol, and propylene glycol as a carrier component; Suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester; And at least one selected from the group consisting of microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, and tracant.
본 발명의 화장료의 제형이 비누인 경우에는 담체 성분으로서 지방산의 알칼리 금속 염, 지방산 헤미에스테르 염, 지방산 단백질 히드롤리제이트, 이세티오네이트, 라놀린 유도체, 지방족 알코올, 식물성 유, 글리세롤, 및 당 등으로 이루어진 군에서 선택된 어느 하나 이상이 이용될 수 있다.When the formulation of the cosmetic composition of the present invention is a soap, the carrier component includes an alkali metal salt of a fatty acid, a fatty acid hemiester salt, a fatty acid protein hydrolizate, an isethionate, a lanolin derivative, an aliphatic alcohol, a vegetable oil, May be used.
또한 본 발명의 화장료 조성물에는 피부 주름 개선 또는 피부 탄력 증진 기능을 가진 물질이 1종 이상 추가로 포함될 수 있다.
The cosmetic composition of the present invention may further comprise at least one substance having the function of improving skin wrinkles or improving skin elasticity.
본 발명은 상기 브레비스카핀(breviscapine) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 주름 개선 또는 피부 탄력 증진용 식품 조성물을 제공한다.The present invention provides a food composition for improving skin wrinkles or skin elasticity comprising Breviscapine or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명의 화합물을 포함하는 식품으로는, 예를 들어 각종 식품류, 음료, 껌, 차, 또는 비타민 복합제 등이 있으며, 이에 제한되는 것은 아니다. 또한, 본 발명의 식품은 정제, 캡슐제, 환제, 또는 액제 등의 형태일 수 있다.Foods containing the compounds of the present invention include, for example, various foods, beverages, gums, tea, and vitamin complexes, but are not limited thereto. In addition, the food of the present invention may be in the form of tablets, capsules, pills, liquids and the like.
본 발명의 피부 주름 개선용 음료 조성물은 지시된 비율로 필수 성분으로서 상기 화합물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 예를 들어 포도당, 과당 등의 모노사카라이드; 말토스, 슈크로스 등의 디사카라이드; 덱스트린, 시클로덱스트린 등의 폴리사카라이드; 및 자일리톨, 소르비톨, 에리트리톨 등의 당 알코올로 이루어진 군에서 선택된 하나 이상일 수 있다. 상술한 것 이외의 향미제로서 예를 들어 타우마틴, 스테비아 추출물(레바우디오시드 A, 글리시르히진 등) 등의 천연 향미제 또는 사카린, 아스파르탐 등의 합성 향미제를 사용할 수 있다. 상기 천연 탄수화물은 조성물 100ml 당 일반적으로 약 1 내지 20g, 바람직하게는 약 5 내지 12g로 포함될 수 있다.The beverage composition for improving skin wrinkles of the present invention is not particularly limited to other ingredients except for containing the above-mentioned compound as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as an additional ingredient have. Such natural carbohydrates include, for example, monosaccharides such as glucose and fructose; Disaccharides such as maltose, sucrose and the like; Polysaccharides such as dextrin and cyclodextrin; And sugar alcohols such as xylitol, sorbitol, erythritol, and the like. As the flavorings other than the above, natural flavors such as tau Martin and stevia extract (rebaudioside A, glycyrrhizin, etc.) or synthetic flavors such as saccharin and aspartame may be used. The natural carbohydrate may be included in an amount of generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition.
또한 본 발명의 식품 조성물은 영양제, 비타민, 광물(전해질), 합성 풍미제, 천연 풍미제, 착색제, 중진제(치즈, 초콜릿 등), 펙트산 또는 그의 염, 알긴산 또는 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 및 탄산화제 등으로 이루어진 군에서 선택된 하나 이상을 함유할 수 있다. 또한 본 발명의 식품 조성물은 천연 과일 주스, 과일 주스 음료, 또는 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 함량은 특별히 제한되는 것은 아니며, 통상적으로 식품 조성물 총 중량 대비 0 내지 20 중량부로 포함될 수 있다.
The food composition of the present invention can also be used as a nutritional supplement, a vitamin, a mineral (electrolyte), a synthetic flavor, a natural flavor, a colorant, a thickening agent (cheese, chocolate etc.), a pectic acid or a salt thereof, A colloid thickening agent, a pH adjusting agent, a stabilizer, a preservative, glycerin, an alcohol, and a carbonating agent. The food composition of the present invention may also contain flesh for the production of natural fruit juices, fruit juice drinks, or vegetable drinks. These components may be used independently or in combination. The content of such an additive is not particularly limited and may be usually 0 to 20 parts by weight based on the total weight of the food composition.
본 발명은 상기 브레비스카핀(breviscapine) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 주름 개선 또는 피부 탄력 증진용 약학적 조성물을 제공한다.The present invention provides a pharmaceutical composition for improving skin wrinkles or improving skin elasticity comprising breviscapine or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명에서, 상기 약학적 조성물은 연고, 크림, 정제, 환제, 산제, 과립제, 캡슐제, 현탁제, 내용액제, 유제, 시럽제, 수용액, 비수성용제, 현탁제, 및 유제로 이루어진 군으로부터 선택되는 제형을 가질 수 있으며, 이에 제한되지는 않는다.In the present invention, the pharmaceutical composition is selected from the group consisting of ointments, creams, tablets, pills, powders, granules, capsules, suspensions, solutions, emulsions, syrups, aqueous solutions, nonaqueous solutions, suspensions, And may be formulated, but is not limited thereto.
본 발명에서, 상기 약학적 조성물은 경구 또는 비경구 등의 여러 가지 제형일 수 있다. 상기 약학적 조성물을 제제화할 경우에는 통상적인 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제, 및 부형제 등으로 이루어진 군에서 선택된 하나 이상을 사용하여 조제할 수 있다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 또는 캡슐제 등이 포함되며, 이러한 고형제제는 예를 들어, 전분, 탄산칼슘, 수크로오스, 락토오스, 또는 젤라틴 등의 부형제를 적어도 하나 이상 혼합하여 조제될 수 있다. 또한 부형제 이외에 스테아린산 마그네슘, 탈크 등과 같은 윤활제들도 사용될 수 있다. 경구투여를 위한 액상제제로는 현탁제, 내용액제, 유제, 또는 시럽제 등이 포함될 수 있는데, 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 등이 포함될 수 있으며, 습윤제, 감미제, 방향제, 또는 보존제 등의 부형제도 포함될 수 있다. 비경구투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 또는 유제가 포함될 수 있다. 비수성용제, 현탁용제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일 등과 같은 식물성 기름, 또는 에틸올레이트 등의 주사 가능한 에스테르 등이 사용될 수 있다.In the present invention, the pharmaceutical composition may be various formulations such as oral or parenteral. When the pharmaceutical composition is formulated, it may be prepared using at least one selected from the group consisting of conventional fillers, extenders, binders, wetting agents, disintegrants, diluents such as surfactants, and excipients. Solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like. Such solid preparations may contain, for example, at least one or more excipients such as starch, calcium carbonate, sucrose, lactose, ≪ / RTI > In addition to excipients, lubricants such as magnesium stearate, talc, and the like may also be used. Liquid preparations for oral administration may include suspensions, solutions, emulsions or syrups, and may be water, liquid paraffin, etc., which are commonly used simple diluents, and may be in the form of wetting agents, sweeteners, Excipients may also be included. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solutions, suspensions, or emulsions. Examples of the non-aqueous solvent and the suspending agent include vegetable oils such as propylene glycol, polyethylene glycol and olive oil, and injectable esters such as ethyl oleate.
본 발명의 화합물의 바람직한 투여량은 대상자의 연령, 성별, 체중, 증상, 질병의 정도, 약물 형태, 투여 경로, 또는 기간 등에 따라 다르지만, 통상의 기술자에 의해 적절하게 선택될 수 있다. 그러나, 바람직한 효과를 위해서, 본 발명의 약학적 조성물은 1일 0.0001 내지 100 mg/kg으로 투여하는 것이 바람직하다. 투여는 하루에 한번 할 수도 있고, 수회 나누어 할 수도 있다. 또한, 그 투여량은 연령, 성별, 체중, 질병의 정도, 또는 투여 경로 등에 따라서 증감될 수 있다. 따라서 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.
The preferred dose of the compound of the present invention varies depending on the age, sex, weight, symptom, degree of disease, drug form, route of administration, or duration of the subject, but can be appropriately selected by a person skilled in the art. However, for the desired effect, the pharmaceutical composition of the present invention is preferably administered at 0.0001 to 100 mg / kg per day. The administration can be done once a day, or divided into several times. In addition, the dose may be increased or decreased according to age, sex, weight, degree of disease, route of administration, and the like. Accordingly, the dosage is not limited in any way to the scope of the present invention.
본 발명은 상기 브레비스카핀(breviscapine) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 콜라겐 합성 촉진제를 제공한다.The present invention provides collagen synthesis promoter comprising Breviscapine or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명의 브레비스카핀(breviscapine)은 생체에 안전하고 피부의 섬유아세포의 제1형 및 제3형의 콜라겐 합성을 촉진함으로써, 피부의 탄력을 향상시키고 피부 주름 개선 효과가 우수하여 콜라겐 합성 촉진제의 유효성분으로 사용된다.Breviscapine of the present invention promotes the synthesis of collagen of type 1 and type 3 of fibroblasts of the skin, which is safe to the living body, thereby improving the elasticity of the skin and improving the skin wrinkle, It is used as a component.
상기 콜라겐 합성 촉진제의 유효성분으로 포함되는 브레비스카핀(breviscapine)은 촉진제 총 중량 대비 0.00001 내지 99.9 중량%로 포함되거나 전체 함량으로도 포함될 수 있으며 유효함량 범위이면 특별히 한정되지는 않는다.
The brevis capine contained as an active ingredient of the collagen synthesis promoter may be included in an amount of 0.00001 to 99.9% by weight based on the total weight of the accelerator, and may be included in the total amount.
또한, 본 발명은 상기 브레비스카핀(breviscapine)을 유효성분으로 포함하는 조성물을 피부에 도포하여 피부 주름을 개선 또는 피부 탄력을 증진시키는 방법을 제공한다.The present invention also provides a method for improving skin wrinkles or improving skin elasticity by applying a composition comprising Breviscapine as an active ingredient to the skin.
본 발명의 화장료, 식품, 또는 약학적 조성물은 강력한 제1형 및 제3형 콜라겐 합성 촉진 활성을 갖는 브레비스카핀(breviscapine)을 포함하여 피부 주름 개선 및 피부 탄력 증진 효과가 우수하다.The cosmetic, food or pharmaceutical composition of the present invention contains brevis capine having strong collagen synthesis promoting activity of type I and type III, and is excellent in skin wrinkle and skin elasticity.
브레비스카핀은 안정성이 우수하여 인체에 무해하고, 이를 포함하는 화장료, 식품, 또는 약학적 조성물은 제형 제작이 용이하며, 제형 안정성 또한 우수하다.Breviscaffin is harmless to the human body because of its excellent stability, and a cosmetic composition, food, or pharmaceutical composition containing the same is easy to formulate and has excellent formulation stability.
이하, 본 발명의 이해를 돕기 위하여 실시예 등을 들어 상세하게 설명하기로 한다. 그러나, 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 하기 실시예들에 한정되는 것으로 해석되어서는 안 된다. 본 발명의 실시예들은 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.
Hereinafter, embodiments of the present invention will be described in detail to facilitate understanding of the present invention. However, the embodiments according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the following embodiments. Embodiments of the invention are provided to more fully describe the present invention to those skilled in the art.
실시예 1: 인체 유래의 섬유아세포에서 브레비스카핀(breviscapine)의 제1형 콜라겐(type I collagen) 합성 촉진 효과 확인Example 1 Confirmation of Promoting the Synthesis of Type 1 Collagen of Breviscapine Type 1 Collagen in Human Fibroblasts
브레비스카핀(breviscapine)을 인간 유래 섬유아세포의 배양액에 첨가하여 세포수준에서 제1형 콜라겐 합성 촉진 효과를 확인하였다. 합성된 콜라겐의 측정은 PICP EIA kit(Procollagen Type I C-Peptide Enzyme Immuno Assay KIT)를 이용하여 정량하였다. 실험에 사용된 브레비스카핀(breviscapine)은 중국 Yuanshi Biothechnology Co. Ltd에서 구입하여 사용하였다.Breviscapine was added to the culture medium of human-derived fibroblasts to confirm the promotion of type I collagen synthesis at the cellular level. The synthesized collagen was quantitated using a PICP EIA kit (Procollagen Type I C-Peptide Enzyme Immuno Assay Kit). The breviscapine used in the experiment was obtained from Yuanshi Biothechnology Co., Ltd., China. Ltd.
실험에서 사용된 브레비스카핀(breviscapine) 시료의 농도는 인간 유래의 섬유아세포(human fibroblast)에 처리 시 독성이 없고, 세포의 증식을 유도하지 않는 범위의 농도로서 최종 1 ㎍/ml, 10 ㎍/ml의 농도를 사용하였다. 세포생존율(cell viability)은 CCK-8(cell counting kit-8, Dojindo Laboratories)을 사용하여 제공된 실험방법에 따라 실시하였다. 하기 표 1에 세포독성 결과를 나타내었다. The concentration of breviscapine sample used in the experiment was not toxic to human fibroblasts treated at the final concentration of 1 ㎍ / ml, 10 ㎍ / ml Was used. Cell viability was performed according to the test method provided using CCK-8 (cell counting kit-8, Dojindo Laboratories). The cytotoxicity results are shown in Table 1 below.
콜라겐 합성량을 측정하기 위해 브레비스카핀(breviscapine)을 섬유아세포의 배양배지(DMEM 배지)에 첨가하여 48 시간 배양한 후 배양액을 취하여 PICP EIA 키트로 각 농도에서 제1형 콜라겐 합성 정도를 분광광도계를 이용하여 450 nm에서 측정하였다.Brevascapine was added to the culture medium of fibroblasts (DMEM medium) for 48 hours to measure the amount of collagen synthesis. After culturing for 48 hours, the degree of collagen type I collagen synthesis was measured with a PICP EIA kit using a spectrophotometer And measured at 450 nm.
효과의 비교를 위하여 시료를 처리하지 않은 섬유아세포의 배양배지(음성대조군)와 비타민 C(양성대조군)를 최종농도 52.85 ㎍/ml가 되도록 첨가한 시료에 대하여 동일한 방법으로 콜라겐 합성 정도를 측정하였다. 콜라겐 생성 증가율은 대조군에 대한 상대적인 콜라겐 생성량의 비율로 계산하고 결과를 하기 표 2에 나타내었다.For the comparison of the effects, the degree of collagen synthesis was measured in the same manner for the samples in which the culture medium of the untreated fibroblasts (negative control) and the vitamin C (positive control) were added to a final concentration of 52.85 / / ml. The increase rate of collagen production was calculated as a ratio of relative collagen production to the control group, and the results are shown in Table 2 below.
상기 표 2의 결과에서 볼 수 있듯이, 브레비스카핀(breviscapine)은 농도의존적으로 콜라겐 합성을 증가시켰고, 일반적으로 콜라겐 합성을 유도하는 것으로 잘 알려진 비타민C를 적용한 경우보다 더 낮은 농도에서 유사한 콜라겐 합성 효과를 나타내었다.
As can be seen from the results in Table 2, breviscapine increased collagen synthesis in a concentration-dependent manner and showed similar collagen synthesis effect at a lower concentration than vitamin C, which is generally known to induce collagen synthesis Respectively.
실시예 2: 인체 유래의 섬유아세포에서 브레비스카핀(breviscapine)의 제3형 콜라겐(type III collagen) 합성 촉진 효과 확인Example 2 Confirmation of Promoting Effect of Breviscapine Type III Collagen Synthesis in Human Fibroblasts
브레비스카핀(breviscapine)을 인간 유래 섬유아세포의 배양액에 첨가하여 세포수준에서 제3형 콜라겐의 합성 촉진 효과를 확인하였다. 합성된 콜라겐의 측정은 EIA kit(Enzyme-linked Immunosorbent Assay KIT) for collagen type III를 이용하여 정량하였다.Breviscapine was added to the culture medium of human-derived fibroblasts to confirm the promotion of the synthesis of type-III collagen at the cell level. The synthesized collagen was quantitated using an EIA kit (Enzyme-linked Immunosorbent Assay Kit) for collagen type III.
실험에서 브레비스카핀(breviscapine)의 최종 농도는 1 ㎍/ml, 10 ㎍/ml가 되도록 하였다. 브레비스카핀(breviscapine)을 인간 유래 섬유아세포(human fibroblast)의 배양배지(DMEM 배지)에 첨가하여 48 시간 배양한 후 배양액을 취하여 EIA 키트로 각 농도에서 콜라겐 합성 정도를 분광광도계를 이용하여 450 nm에서 측정하였다.The final concentration of breviscapine in the experiment was 1 ㎍ / ml, 10 ㎍ / ml. Breviscapine was added to the culture medium of human fibroblast (DMEM medium) for 48 hours, and the culture solution was taken. The degree of collagen synthesis at each concentration was measured by EIA kit at 450 nm using a spectrophotometer Respectively.
효과 비교를 위하여 아무것도 첨가하지 않은 섬유아세포의 배양배지(음성대조군)와 비타민 C(양성대조군)를 최종농도 52.85 ㎍/ml가 되도록 첨가한 시료에 대하여 동일한 방법으로 제3형 콜라겐의 합성 정도를 측정하였다.For the comparison of effects, the degree of synthesis of type 3 collagen was measured in the same manner for the sample to which the culture medium (negative control) and the vitamin C (positive control) were added so as to have a final concentration of 52.85 / / ml without any addition of fibroblasts Respectively.
콜라겐 생성 증가율은 대조군에 대한 상대적인 콜라겐 생성량의 비율로 계산하고 결과를 하기 표 3에 나타내었다.The increase rate of collagen production was calculated as a ratio of relative collagen production to the control group, and the results are shown in Table 3 below.
상기 표 3의 결과에서 볼 수 있듯이, 브레비스카핀(breviscapine)은 물질을 처리하지 않은 음성대조군과 비교하여 농도의존적으로 제3형 콜라겐을 증가시킴으로써 우수한 콜라겐 합성 효과를 나타내었다.
As can be seen from the results of Table 3, breviscapine exhibited an excellent collagen synthesis effect by increasing type-III collagen in a concentration-dependent manner compared to a negative control without substance treatment.
제조예 1 및 비교예 1: 피부 외용연고의 제조Production Example 1 and Comparative Example 1: Production of ointment for external use
하기 표 4의 조성과 같이 브레비스카핀(breviscapine)을 유효성분으로 포함하는 피부 외용연고를 통상의 방법에 따라 제조하였다. 또한, 유효성분을 제외한 나머지 성분으로 제조한 피부 외용연고를 비교예 1로 제조하였다.Skin external ointment containing brevis capine as an active ingredient was prepared according to a conventional method as shown in the composition of Table 4 below. In addition, the ointment for external use for skin prepared from the other ingredients except for the active ingredient was prepared in Comparative Example 1.
에테르 포스페이트Polyoxyethylene oleyl
Ether phosphate
제조예 2 및 비교예 2: 화장료 에센스의 제조Production Example 2 and Comparative Example 2: Production of cosmetic essence
브레비스카핀(breviscapine)을 유효성분으로 포함하는 화장료 에센스의 제형을 제조예 2로, 유효성분을 포함하지 않는 것을 제외하고는 제조예 2와 동일하게 제조한 것을 비교예 2로 하였다. 상세한 조성은 하기 표 5에 나타내었다.Comparative Example 2 was prepared in the same manner as in Preparation Example 2 except that the formulation of the cosmetic essence containing Brevis capine as an active ingredient was used as Preparation Example 2 and the composition containing no active ingredient was used. The detailed composition is shown in Table 5 below.
제조예 3 및 비교예 3: 화장료 크림의 제조Production Example 3 and Comparative Example 3: Production of cosmetic cream
브레비스카핀(breviscapine)을 유효성분으로 포함하는 화장료 크림의 제형을 제조예 3으로, 유효성분을 포함하지 않는 것을 제외하고는 제조예 3와 동일하게 제조한 것을 비교예 3으로 하였다. 상세한 조성은 하기 표 6에 나타내었다.The preparation of cosmetic cream containing brevis capine as an active ingredient was prepared in the same manner as in Preparation Example 3 except that the active ingredient was not added. The detailed composition is shown in Table 6 below.
실시예 3: 패널 테스트를 통한 피부 주름 개선 효과 확인Example 3: Confirmation of skin wrinkle improvement effect through panel test
상기 제조예 2와 비교예 2의 에센스에 대해서 건강한 35세에서 50세의 여성을 대상으로 피부 주름 개선 효과를 다음과 같이 시험하였다.For the essences of Preparation Example 2 and Comparative Example 2, the skin wrinkle-reducing effect was tested as follows for healthy 35- to 50-year-old women.
35세에서 50세까지의 여성 30명을 15명씩 2개의 군으로 구분하고 1군은 브레비스카핀(breviscapine)을 0.5% 포함하는 제조예 2의 에센스를, 2군은 비교예 2의 에센스를 안면부에 1일 1회 3개월간 도포하였다. 3개월 후 피부 주름의 개선 정도를 피험자의 설문을 통해 평가하였다. 피험자의 설문은 피부 주름 개선에 관하여 사용전과 비교하여 개선 없음, 약간의 개선, 상당한 개선의 3단계로 판정하였으며, 그 결과는 하기 표 7에 나타내었다.30 women aged 35 to 50 years were divided into two groups by 15 persons. Group 1 contained the essence of Preparation Example 2 containing 0.5% Breviscapine, Group 2 was the essence of Comparative Example 2, Once a day for 3 months. After 3 months, the improvement of skin wrinkles was evaluated by questionnaires. The subjects' questionnaires were judged to be three stages of improvement of the wrinkles of the skin, no improvement, slight improvement and considerable improvement as compared with before use, and the results are shown in Table 7 below.
상기 표 7에서 볼 수 있듯이, 브레비스카핀(breviscapine) 0.5 중량%를 포함한 제조예 2의 에센스를 사용한 경우, 사용하지 않은 비교예 2의 에센스를 사용한 경우보다 피부 주름 개선 효과가 우수함을 확인할 수 있었다.
As can be seen from the above Table 7, it was confirmed that when the essence of Preparation Example 2 containing 0.5% by weight of breviscapine was used, the skin wrinkle-reducing effect was superior to that of the essence of Comparative Example 2 which was not used.
실시예 4: 영상분석을 통한 화장료 에센스의 주름개선효과 시험Example 4: Effect of wrinkle improvement test of cosmetic essence through image analysis
영상분석을 통하여 상기 제조예 2 및 비교예 2의 에센스에 대해서 주름 개선 효과를 평가하였다. 구체적으로, 실험이 시작되기 전, 눈 밑의 레플리카(replica)를 채취하고(Xantopren, Bayer), 실험이 종료된 직후 레플리카를 눈 밑의 동일 부위에서 채취하여 영상분석을 통해 피부 주름의 2차원적 분석으로 피부 주름의 밀도를 측정하였다. 영상 분석에 의한 피부 주름 밀도의 감소율은 에센스의 사용 전 피부 주름 밀도에 대한 사용 후 피부 주름 밀도의 비를 평균한 값이며, 상기 측정 결과를 하기 표 8에 나타내었다.The wrinkle-improving effect was evaluated for the essences of Preparation Example 2 and Comparative Example 2 through image analysis. Specifically, the replica under the eye was sampled (Xantopren, Bayer) before the experiment was started, and the replica was sampled from the same site under the eyes immediately after the experiment was completed. The density of skin wrinkles was measured by analysis. The reduction rate of the skin wrinkle density by image analysis is a value obtained by averaging the ratio of the skin wrinkle density after use to the skin wrinkle density before use of the essence, and the measurement results are shown in Table 8 below.
상기 표 8에서 알 수 있듯이, 브레비스카핀(breviscapine)을 포함한 제조예 2의 에센스를 사용한 경우, 브레비스카핀(breviscapine)을 포함하지 않은 비교예 2의 에센스를 사용한 경우보다 피부 주름 개선 효과가 우수함을 알 수 있었다. 또한 상기 시험 과정에서 제조예 2의 에센스에 의한 피부 자극이나 부작용은 발견되지 않았다.
As can be seen from the above Table 8, when the essence of Preparation Example 2 containing Breviscapine was used, it was found that the effect of improving skin wrinkles was superior to that of the essence of Comparative Example 2 containing no breviscapine I could. No skin irritation or side effects due to the essence of Preparation Example 2 were found in the above test procedure.
실시예 5: 화장료 크림의 피부 탄력 개선 효과 시험Example 5: Test for improving skin elasticity of cosmetic cream
본 발명의 브레비스카핀(breviscapine)를 함유하는 화장료에 대한 피부 탄력 증진 효과를 사람 피부에 적용하기 위해 22°C 및 상대습도 50%의 항온 항습실에서 상기 제조예 3 및 비교예 3의 크림을 건강한 성인 30명의 목가에 4주간 도포한 후 도포 전, 후의 탄력을 측정하여 피부탄력 개선효과를 비교 평가하였다. 피검자의 목가 왼쪽 부위에는 제조예 3 크림을, 오른쪽 부위에는 비교예 3 크림을 1일 2회씩 아침, 저녁으로 4주간 세안 후 사용하도록 하였다. 그 후, 피부탄력측정기(cutometer, C+K, Germany)를 이용하여 각 부위에서의 탄력의 개선 정도를 측정하였다. 개선 정도는 Ur/Uf를 parameter로 사용하였다.In order to apply the skin elasticity-enhancing effect of the cosmetic composition containing breviscapine of the present invention to human skin, the creams of Preparation Example 3 and Comparative Example 3 were applied to a healthy adult at 22 ° C and a relative humidity of 50% After applying for 4 weeks to 30 people, elasticity was measured before and after application, and skin elasticity improvement effect was compared and evaluated. In the left side of the subject's neck, Preparation Example 3 cream was used, and in the right side, Comparative Example 3 cream was used twice a day in morning and evening after cleansing for 4 weeks. After that, the degree of improvement of elasticity at each site was measured using a skin elasticity meter (cutometer, C + K, Germany). The degree of improvement was used as a parameter of Ur / Uf.
상기 표 9에서 알 수 있듯이, 브레비스카핀(breviscapine)을 포함한 제조예 3의 크림을 사용한 경우, 브레비스카핀(breviscapine)을 포함하지 않은 비교예 3의 크림를 사용한 경우보다 피부 탄력 개선 효과가 우수함을 알 수 있다. 또한 상기 시험 과정에서 제조예 3의 크림에 의한 피부 자극이나 부작용은 발견되지 않았다.As can be seen from the above Table 9, when the cream of Preparation Example 3 containing Breviscapine was used, it was found that the skin elasticity improvement effect was superior to that of the cream of Comparative Example 3 which did not contain Breviscapine have. In addition, skin irritation or side effects caused by the cream of Preparation Example 3 were not found in the above test procedure.
Claims (5)
A method for improving skin wrinkles or improving skin elasticity by applying a composition comprising brevis capine as an active ingredient to the skin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140115382A KR20160026452A (en) | 2014-09-01 | 2014-09-01 | Compositions for improving skin wrinkle or enhancing skin elasticity comprising breviscapine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140115382A KR20160026452A (en) | 2014-09-01 | 2014-09-01 | Compositions for improving skin wrinkle or enhancing skin elasticity comprising breviscapine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160026452A true KR20160026452A (en) | 2016-03-09 |
Family
ID=55536843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020140115382A Ceased KR20160026452A (en) | 2014-09-01 | 2014-09-01 | Compositions for improving skin wrinkle or enhancing skin elasticity comprising breviscapine |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20160026452A (en) |
-
2014
- 2014-09-01 KR KR1020140115382A patent/KR20160026452A/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20160054668A (en) | Composition for promoting synthesis of hyaluronic acid comprising Taraxacum herbs extracts and the use thereof | |
| KR101453610B1 (en) | Compositions for improving skin wrinkle or enhancing skin elasticity comprising geniposide as an active ingredient | |
| KR20140051763A (en) | Cosmetic composition for anti-wrinkle | |
| KR20170073308A (en) | Composition for improving the skin | |
| KR20170078259A (en) | Composition for improving skin conditions comprising Isosteviol | |
| KR20170067287A (en) | Composition for improving the skin | |
| KR20170079977A (en) | Composition for improving skin conditions comprising Praeruptorin A | |
| KR101481226B1 (en) | Compositions for improving skin wrinkle or enhancing skin elasticity comprising rebaudioside as an active ingredient | |
| KR102503107B1 (en) | Composition for improving skin conditions comprising Polygalasaponin F | |
| KR101516478B1 (en) | Composition for improving elasticity and wrinkles of skin | |
| KR102348149B1 (en) | Cosmetic or pharmaceutical composition for melanism, elasticity, anti-wrinkle, or skin moisturizing comprising parthenolide | |
| KR102204367B1 (en) | Cosmetic compositions for improving skin wrinkle | |
| KR101656321B1 (en) | Composition for improving skin wrinkles or skin elasticity comprising dioscine 7-O-beta-D-glucopyranoside | |
| KR20160026443A (en) | Compositions for improving skin wrinkle or enhancing skin elasticity comprising loganic acid | |
| KR101656322B1 (en) | Compositions for improving skin wrinkle or enhancing skin elasticity comprising gardenoside | |
| KR101452582B1 (en) | Compositions for improving skin wrinkle or enhancing skin elasticity comprising tetrahydropalmatine as an active ingredient | |
| KR20160054681A (en) | Composition for promoting synthesis of hyaluronic acid comprising Polygala tenuifolia Willd extracts and the use thereof | |
| KR102261933B1 (en) | Composition for improving skin conditions comprising 4-(4-Hydroxyphenyl)-2-butanone | |
| KR20160054672A (en) | Composition for promoting synthesis of hyaluronic acid comprising Hordeum vulgare extracts and the use thereof | |
| KR20160026452A (en) | Compositions for improving skin wrinkle or enhancing skin elasticity comprising breviscapine | |
| KR102337297B1 (en) | Cosmetic or pharmaceutical composition for skin elasticity, anti-wrinkle, or skin moisturizing comprising sophoricoside or a pharmaceutically acceptable salt thereof | |
| KR102348148B1 (en) | Cosmetic or pharmaceutical composition for melanism, elasticity, anti-wrinkle, or skin moisturizing comprising dihydroartemisinin | |
| KR101434034B1 (en) | Compositions for improving skin wrinkle or enhancing skin elasticity comprising forsythin as an active ingredient | |
| KR101505712B1 (en) | Compositions for improving skin wrinkle or enhancing skin elasticity comprising hypaconitine as an active ingredient | |
| KR102418909B1 (en) | Composition for improving skin conditions comprising 8-Gingerol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20140901 |
|
| PA0201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20151120 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20160229 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20151120 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| PG1501 | Laying open of application |